Document is current
Any future updates will be listed below
-
Authors
Javed, Sohail Rooman
Skolariki, Aglaia
Zameer, Mohammed Zeeshan
Lord, Simon R. https://orcid.org/0000-0001-7946-5609
- License Information
-
More Information
Article History
Received: 21 April 2024
Revised: 13 August 2024
Accepted: 19 August 2024
First Online: 9 September 2024
Competing interests
: SL—Honoraria: Eisai, Prosigna, Roche, Pfizer, Novartis, Sanofi. Advisory: Shionogi, Sanofi, GLG Consulting: Rejuversen, Oxford Biodynamics. Research grant funding: CRUK, NIHR, Against Breast Cancer, Pathios Therapeutics. Travel/Accommodation/ Expenses: Pfizer, Roche, Synthon, Piqur Therapeutics. Stock holding: Mitox Therapeutics. Previous employment: Pfizer. My institution has received funding for clinical trials for which I am chief investigator or principal investigator from: Cancer Research UK, Boehringer Ingelheim, Piqur Therapeutics, AstraZeneca, Carrick Therapeutics, Sanofi, Merck KGaA, Synthon, Roche, Exscientia, BioInvent, RS Oncology. The remaining authors declare no competing interests.
